Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M4EF
|
|||
| Former ID |
DNC006277
|
|||
| Drug Name |
C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
|
|||
| Synonyms |
CHEMBL427205; c[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C42H59N11O7
|
|||
| Canonical SMILES |
CCCCC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)C(C)C
|
|||
| InChI |
1S/C42H59N11O7/c1-4-5-15-30-38(57)53-35(24(2)3)41(60)52-32(21-25-12-7-6-8-13-25)39(58)50-31(17-11-20-46-42(44)45)37(56)51-33(22-26-23-47-28-16-10-9-14-27(26)28)40(59)49-29(36(43)55)18-19-34(54)48-30/h6-10,12-14,16,23-24,29-33,35,47H,4-5,11,15,17-22H2,1-3H3,(H2,43,55)(H,48,54)(H,49,59)(H,50,58)(H,51,56)(H,52,60)(H,53,57)(H4,44,45,46)/t29-,30-,31-,32+,33-,35-/m0/s1
|
|||
| InChIKey |
STHTUYXXUBUJIE-NMIKHESWSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor (MCR) | Target Info | Inhibitor | [1] |
| Melanocortin receptor 3 (MC3R) | Target Info | Inhibitor | [1] | |
| Melanocortin receptor 4 (MC4R) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.